Data / Drug companies / Thea Pharma Inc.
Thea Pharma Inc.: 11 products in the FDA NDC directory, labeler code 82584
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Thea Pharma Inc. (labeler code 82584) lists 11 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 9 prescription drugs, 2 over the counter drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on February 26, 2026.
The request: Watch Thea Pharma Inc. (FDA labeler code 82584): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 82584
- Products in commercial distribution
- 11
- Packages
- 17
- Finished drugs by generic name
- 8
- Prescription products
- 9
- Over the counter products
- 2
- Flagged as original packager
- 11 of 11 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- October 28, 2022
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 9 | 81.8% |
| Over the counter monograph drugs | 2 | 18.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 9 | 81.8% |
| Over the counter drugs | 2 | 18.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Povidone | 2 | 1 |
| Timolol | 2 | 1 |
| Dorzolamide hydrochloride and timolol maleate | 2 | 11 |
| Latanoprost ophthalmic solution 0.005% | 1 | 1 |
| Bimatoprost | 1 | 15 |
| Tafluprost | 1 | 4 |
| Azithromycin monohydrate | 1 | 7 |
| Lidocaine hydrochloride anhydrous | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution/ drops | 8 | 72.7% |
| Gel | 3 | 27.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| beta-Adrenergic Blocker | 4 |
| Carbonic Anhydrase Inhibitor | 2 |
| Prostaglandin Analog | 2 |
| Macrolide Antimicrobial | 1 |
| Amide Local Anesthetic | 1 |
| Antiarrhythmic | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Zolymbus | 82584-010 | Gel | New drug applications (NDA) | February 26, 2026 |
| IVIZIA Lubricant Eye Gel | 82584-701 | Gel | Over the counter monograph drugs | December 1, 2024 |
| IVIZIA Dry Eye | 82584-700 | Solution/ drops | Over the counter monograph drugs | December 1, 2024 |
| Iyuzeh | 82584-003 | Solution/ drops | New drug applications (NDA) | July 14, 2023 |
| Cosopt pf | 82584-604 | Solution/ drops | New drug applications (NDA) | December 10, 2022 |
| Akten | 82584-792 | Gel | New drug applications (NDA) | December 1, 2022 |
| Betimol | 82584-001 | Solution/ drops | New drug applications (NDA) | December 1, 2022 |
| Betimol | 82584-002 | Solution/ drops | New drug applications (NDA) | November 15, 2022 |
| Cosopt | 82584-605 | Solution/ drops | New drug applications (NDA) | November 10, 2022 |
| Azasite | 82584-307 | Solution/ drops | New drug applications (NDA) | November 1, 2022 |
| Zioptan | 82584-609 | Solution/ drops | New drug applications (NDA) | October 28, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.